Aptevo Therapeutics Stock Analysis

APVO Stock  USD 4.06  0.05  1.25%   
Aptevo Therapeutics is overvalued with Real Value of 3.9 and Target Price of 8.38. The main objective of Aptevo Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Aptevo Therapeutics is worth, separate from its market price. There are two main types of Aptevo Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Aptevo Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Aptevo Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Aptevo Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Aptevo Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Aptevo Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Aptevo Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.

Aptevo Stock Analysis Notes

The company has price-to-book (P/B) ratio of 0.22. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aptevo Therapeutics recorded a loss per share of 67.07. The entity last dividend was issued on the 27th of March 2020. The firm had 1:44 split on the 6th of March 2024. Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Aptevo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 54 people. For more info on Aptevo Therapeutics please contact Marvin White at 206 838 0500 or go to https://www.aptevotherapeutics.com.

Aptevo Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aptevo Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aptevo Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aptevo Therapeutics generated a negative expected return over the last 90 days
Aptevo Therapeutics has high historical volatility and very poor performance
Aptevo Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (18.65 M) with profit before overhead, payroll, taxes, and interest of 3.11 M.
Aptevo Therapeutics currently holds about 29.43 M in cash with (11.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from news.google.com: Aptevo Therapeutics Inc. Short Interest Update - Defense World

Aptevo Therapeutics Upcoming and Recent Events

Earnings reports are used by Aptevo Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aptevo Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Aptevo Largest EPS Surprises

Earnings surprises can significantly impact Aptevo Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-11-14
2023-09-30-0.75-0.50.2533 
2021-08-12
2021-06-30-2-1.750.2512 
2022-05-12
2022-03-31-1.15-1.55-0.434 
View All Earnings Estimates

Aptevo Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Aptevo Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aptevo Therapeutics backward and forwards among themselves. Aptevo Therapeutics' institutional investor refers to the entity that pools money to purchase Aptevo Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Tower Research Capital Llc2023-12-31
13.7 K
Morgan Stanley - Brokerage Accounts2023-12-31
11.4 K
Two Sigma Securities, Llc2023-12-31
11.2 K
Franklin Resources Inc2023-12-31
11 K
State Street Corporation2023-12-31
10.9 K
Divergent Wealth Advisors, Llc2023-12-31
10 K
Jpmorgan Chase & Co2023-12-31
1.9 K
Wells Fargo & Co2023-12-31
1.6 K
Fifth Third Bancorp2023-12-31
291
Renaissance Technologies Corp2023-12-31
516.8 K
Sabby Management Llc2023-12-31
349.5 K
Note, although Aptevo Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aptevo Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.72 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aptevo Therapeutics's market, we take the total number of its shares issued and multiply it by Aptevo Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Aptevo Profitablity

Aptevo Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Aptevo Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Aptevo Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Aptevo Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Aptevo Therapeutics' profitability requires more research than a typical breakdown of Aptevo Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2024
Return On Capital Employed(1.64)(1.72)
Return On Assets(0.70)(0.67)
Return On Equity(1.42)(1.50)

Management Efficiency

Aptevo Therapeutics has return on total asset (ROA) of (0.6112) % which means that it has lost $0.6112 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2353) %, meaning that it created substantial loss on money invested by shareholders. Aptevo Therapeutics' management efficiency ratios could be used to measure how well Aptevo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to drop to -1.72. In addition to that, Return On Assets is likely to grow to -0.67. At this time, Aptevo Therapeutics' Net Tangible Assets are very stable compared to the past year. As of the 28th of March 2024, Other Current Assets is likely to grow to about 2.3 M, while Total Assets are likely to drop about 23.6 M.
Last ReportedProjected for 2024
Price Book Value Ratio 0.18  0.17 
Enterprise Value Multiple 0.33  0.34 
Price Fair Value 0.18  0.17 
The analysis of Aptevo Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Aptevo Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Aptevo Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
4.912

Technical Drivers

As of the 28th of March, Aptevo Therapeutics shows the Risk Adjusted Performance of (0.06), standard deviation of 6.53, and Mean Deviation of 4.53. Aptevo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for Aptevo Therapeutics, which can be compared to its rivals. Please confirm Aptevo Therapeutics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Aptevo Therapeutics is priced correctly, providing market reflects its regular price of 4.06 per share. Given that Aptevo Therapeutics has information ratio of (0.15), we suggest you to validate Aptevo Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Aptevo Therapeutics Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Aptevo Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Aptevo Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Aptevo Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aptevo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aptevo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aptevo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Aptevo Therapeutics Predictive Daily Indicators

Aptevo Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aptevo Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Aptevo Therapeutics Corporate Filings

S1
20th of March 2024
Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC)
ViewVerify
8K
7th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
5th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
14th of February 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
8K
6th of February 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
30th of January 2024
Other Reports
ViewVerify
16th of January 2024
Other Reports
ViewVerify
22nd of December 2023
Other Reports
ViewVerify

Aptevo Therapeutics Forecast Models

Aptevo Therapeutics' time-series forecasting models are one of many Aptevo Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aptevo Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Aptevo Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aptevo Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aptevo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Aptevo Therapeutics. By using and applying Aptevo Stock analysis, traders can create a robust methodology for identifying Aptevo entry and exit points for their positions.
Last ReportedProjected for 2024
Pretax Profit Margin 2.03  2.13 
Operating Profit Margin(8.28)(8.69)
Net Profit Margin 12.33  12.95 
Gross Profit Margin 0.82  0.44 

Current Aptevo Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aptevo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aptevo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
8.38Strong Buy2Odds
Aptevo Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Aptevo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aptevo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aptevo Therapeutics, talking to its executives and customers, or listening to Aptevo conference calls.
Aptevo Analyst Advice Details

Aptevo Stock Analysis Indicators

Aptevo Therapeutics stock analysis indicators help investors evaluate how Aptevo Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aptevo Therapeutics shares will generate the highest return on investment. By understating and applying Aptevo Therapeutics stock analysis, traders can identify Aptevo Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow22.6 M
Common Stock Shares Outstanding278.1 K
Total Stockholder Equity12.2 M
Property Plant And Equipment Net5.8 M
Cash And Short Term Investments16.9 M
Cash16.9 M
Accounts PayableM
Net Debt-11.5 M
50 Day M A6.1665
Total Current Liabilities7.2 M
Other Operating Expenses28.9 M
Non Current Assets Total5.8 M
Forward Price Earnings3.9448
Stock Based Compensation2.2 M
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Aptevo Stock analysis

When running Aptevo Therapeutics' price analysis, check to measure Aptevo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aptevo Therapeutics is operating at the current time. Most of Aptevo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aptevo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aptevo Therapeutics' price. Additionally, you may evaluate how the addition of Aptevo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Transaction History
View history of all your transactions and understand their impact on performance
Is Aptevo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(67.07)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.61)
Return On Equity
(1.24)
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.